Peptide-Drug Conjugates: A New Hope for Targeted Cancer Therapy
Review of peptide-drug conjugates as cancer therapeutics covers design principles, targeting mechanisms, clinical candidates, and advantages over antibody-drug conjugates.
Quick Facts
What This Study Found
Review of peptide-drug conjugates as cancer therapeutics covers design principles, targeting mechanisms, clinical candidates, and advantages over antibody-drug conjugates.
Key Numbers
Only one PDC (Lutathera) currently FDA-approved. Pepaxto was approved then withdrawn from market.
How They Did This
In publication.
Why This Research Matters
Relevant to peptide therapeutics.
The Bigger Picture
Advances peptide evidence.
What This Study Doesn't Tell Us
In publication.
Questions This Raises
- ?Long-term implications?
- ?Evidence comparison?
- ?Next steps?
Trust & Context
- Key Stat:
- Key finding Review of peptide-drug conjugates as cancer therapeutics covers design principles, targeting mechani
- Evidence Grade:
- Based on design.
- Study Age:
- Published in 2025.
- Original Title:
- Peptide-Drug Conjugates: A New Hope for Cancer.
- Published In:
- Journal of peptide science : an official publication of the European Peptide Society, 31(8), e70040 (2025)
- Database ID:
- RPEP-09978
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What does this mean?
Review of peptide-drug conjugates as cancer therapeutics covers design principles, targeting mechanisms, clinical candidates, and advantages over antibody-drug conjugates.
How reliable?
Consult publication.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09978APA
Armstrong, Amy; Coburn, Fleur; Nsereko, Yanyamba; Al Musaimi, Othman. (2025). Peptide-Drug Conjugates: A New Hope for Cancer.. Journal of peptide science : an official publication of the European Peptide Society, 31(8), e70040. https://doi.org/10.1002/psc.70040
MLA
Armstrong, Amy, et al. "Peptide-Drug Conjugates: A New Hope for Cancer.." Journal of peptide science : an official publication of the European Peptide Society, 2025. https://doi.org/10.1002/psc.70040
RethinkPeptides
RethinkPeptides Research Database. "Peptide-Drug Conjugates: A New Hope for Cancer." RPEP-09978. Retrieved from https://rethinkpeptides.com/research/armstrong-2025-peptidedrug-conjugates-a-new
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.